#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Nicole Crawford Email
VP Sales, Radioligand Therapy . Advanced Accelerator Applications
New York, NY
LocationPrimary Email
How to contact Nicole Crawford
Join and see Nicole's contact info for free!Current Roles
Employees:
1037Revenue:
$333.5MAbout
Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products. AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology. AAA’s lead therapeutic product candidate, Lutathera, is a novel MNM compound under development for the treatment of midgut neuroendocrine tumors, or NETs, a significant unmet medical need. Lutathera is a Lutetium-177, or Lu-177, labeled somatostatin analogue peptide that has received orphan drug designation from the European Medicines Agency, or EMA, and the U.S. Food and Drug Administration, or FDA. Orphan drug designation is a special status conferred by the FDA and EMA to a product candidate that treats a rare disease or condition, and the designation entitles the product candidate’s sponsor to various development incentives. Lutathera was also granted Fast-Track designation by the FDA in April 2015 for the treatment of inoperable progressive midgut NETs. In a pivotal Phase 3 trial for the treatment of inoperable progressive midgut NETs, Lutathera has produced favorable initial results compared to the current standard of care, treatment with Octreotide LAR aloneAdvanced Accelerator Applications Address
350 Fifth AvenueNew York, NY
United States